Sesha Sridevi Alluri

This inventor holds 11 USPTO granted patents. Top assignees: Reddy US Therapeutics, Inc., Reddy U5 Therapeutics, Inc., Stevens Institute of Technology. Active years: 2006-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sesha Sridevi Alluri. Retrieved from https://idiyas.com/inventor/sesha-sridevi-alluri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 9.1

Average Co-Inventor Count = 10.2

ph-index = 4

Forward Citations = 89(Granted Patents)

Location History:

Hyderabad, IN (2006 - 2007)
Edison, NJ (US) (2007 - 2008)
Grandhinagar, IN (2008)
Redmond, WA (US) (2008)
Piscataway, NJ (US) (2008 - 2012)

Company Filing History:

9 out of 19

Reddy US Therapeutics, Inc.

patents

1 out of 1

Reddy U5 Therapeutics, Inc.

patent

1 out of 186

Stevens Institute of Technology

patents

Years Active: 2006-2012

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8283346 - Human immunodeficiency virus protease inhibitors (2012-10-09),

2. 7335770 - Triazine compounds and their analogs, compositions, and methods (2008-02-26),

3. 7335656 - Medical devices employing triazine compounds and compositions thereof (2008-02-26),

4. 7332490 - Methods and compositions of novel triazine compounds (2008-02-19),

5. 7332489 - Methods and compositions of novel triazine compounds (2008-02-19),

6. 7332488 - Methods and compositions of novel triazine compounds (2008-02-19),

7. 7268134 - Medical devices employing triazine compounds and compositions thereof (2007-09-11),

8. 7265114 - Methods and compositions of novel triazine compounds (2007-09-04),

9. 7238692 - Medical devices employing triazine compounds and compositions thereof (2007-07-03),

10. 7169785 - Methods and compositions of novel triazine compounds (2007-01-30),

11. 7132423 - Methods and compositions of novel triazine compounds (2006-11-07),

Title: Sesha Sridevi Alluri: Innovator in Medical Therapeutics

Introduction

Sesha Sridevi Alluri is a prominent inventor based in Hyderabad, Telangana, India. She has made significant contributions to the field of medical therapeutics, holding a total of 11 patents. Her work primarily focuses on developing innovative solutions for treating various health conditions, particularly those related to viral infections and inflammatory responses.

Latest Patents

Among her latest patents is a groundbreaking invention related to human immunodeficiency virus (HIV) protease inhibitors. This invention encompasses novel compounds, pharmaceutical compositions, and methods for utilizing these inhibitors to treat HIV and related disorders. Another notable patent involves medical devices that employ triazine compounds. This invention addresses pathophysiological conditions arising from inflammatory responses and includes methods and compounds that inhibit smooth muscle proliferation, which is crucial for treating vascular occlusive conditions such as restenosis and atherosclerosis.

Career Highlights

Sesha has worked with notable companies, including Reddy US Therapeutics, Inc. and Reddy U5 Therapeutics, Inc. Her career reflects a commitment to advancing medical technology and improving patient outcomes through innovative research and development.

Collaborations

Throughout her career, Sesha has collaborated with esteemed colleagues, including Richard T. Timmer and Christopher W. Alexander. These partnerships have further enhanced her research and contributed to her success as an inventor.

Conclusion

Sesha Sridevi Alluri stands out as a leading innovator in the medical field, with a focus on developing effective treatments for complex health issues. Her contributions through patents and collaborations continue to impact the landscape of medical therapeutics.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]